1 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al. Adrenocortical carcinoma. Endocr Rev 2014; 35: 282-326.
2 Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 273-289.
3 Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 2010; 17: 263-270.
4 Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumours. Eur J Endocrinol 2018; 179: G1-G46.
5 Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013; 49: 2579-2586.
6 Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380.
7 Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab 2017; 102: 1358-1365.
8 Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M et al. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab 2018; 103: 1686-1695.
9 Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15: 1043-1053.
10 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197.
11 Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 2016; 30: 363.
12 Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM et al. Mutations of beta-catenin in adrenocortical tumours: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumours. Cancer Res 2005; 65: 7622-7627.
13 Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46: 607-612.
14 Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL et al. Distinct transcriptional profiles of adrenocortical tumours uncovered by DNA microarray analysis. Am J Pathol 2003; 162: 521-531.
15 Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J et al. Molecular classification and prognostication of adrenocortical tumours by transcriptome profiling. Clin Cancer Res 2009; 15: 668-676.
16 Liang R, Weigand I, Lippert J, Kircher S, Altieri B, Steinhauer S et al. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Front Endocrinol (Lausanne) 2020; 11: 219.
17 Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 2015; 16: 426-435.
18 Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2020; 34: 101434.
19 Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97: E476-485.
20 Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: E119-125.
21 Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 2013; 31: 3012-3018.
22 Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 2017; 552: 116-120.
23 Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumour mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer 2019; 7: 183.
24 Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumour trial. J Immunother Cancer 2018; 6: 111.
25 Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 2019; 7: 253.
26 Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB et al. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab 2019; 104: 6193-6200.
27 Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol 2020; 38: 71-80.
28 Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM et al. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumour Microenvironment. J Clin Endocrinol Metab 2020; 105.
29 Volkov NM, Yanus GA, Ivantsov AO, Moiseenko FV, Matorina OG, Bizin IV et al. Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. Invest New Drugs 2020; 38: 894-898.
30 Pilati C, Shinde J, Alexandrov LB, Assie G, Andre T, Helias-Rodzewicz Z et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol 2017; 242: 10-15.
31 Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M et al. Interplay between glucocorticoids and tumour-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer 2020; 8.
32 Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990; 50: 5488-5496.
33 Pinto EM, Kiseljak-Vassiliades K, Hantel C. Contemporary preclinical human models of adrenocortical carcinoma. Curr Opin Endocr Metab Res 2019; 8: 139-144.
34 Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M et al. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumour models to improve clinical translation. Oncotarget 2016; 7: 79292-79304.
35 Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 2018; 25: 437-451.
36 Weigand I, Schreiner J, Rohrig F, Sun N, Landwehr LS, Urlaub H et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis 2020; 11: 192.
37 Siebert C, Ciato D, Murakami M, Frei-Stuber L, Perez-Rivas LG, Monteserin-Garcia JL et al. Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. Front Endocrinol (Lausanne) 2019; 10: 487.
38 Kiseljak-Vassiliades K, Zhang Y, Kar A, Razzaghi R, Xu M, Gowan K et al. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology 2018; 159: 2532-2544.
39 Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180: 599-607.
40 Motulsky HJ. Confidence intervals of parameters, GraphPad Curve Fitting Guide2016.
41 Kurlbaum M, Sbiera S, Kendl S, Fassnacht M, Kroiss M. Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. Exp Clin Endocrinol Diabetes 2020.
42 Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet journal, 2011; 17: 10-12.
43 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
44 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
45 McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
46 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
47 Goncearenco A, Rager SL, Li M, Sang QX, Rogozin IB, Panchenko AR. Exploring background mutational processes to decipher cancer genetic heterogeneity. Nucleic Acids Res 2017; 45: W514-W522.
48 Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L et al. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology 2015; 156: 3895-3908.
49 Viel A, Bruselles A, Meccia E, Fornasarig M, Quaia M, Canzonieri V et al. A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine 2017; 20: 39-49.
50 Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumours. J Clin Endocrinol Metab 2010; 95: E161-171.
51 AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T et al. Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet 2018; 102: 401-414.
52 Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science 2017; 357: 409-413.
53 Mota JM, Sousa LG, Braghiroli MI, Siqueira LT, Neto JEB, Chapchap P et al. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports. Medicine 2018; 97.
54 Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT et al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumours. Nat Genet 2002; 30: 227-232.
55 Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol 2011; 79: 1-16.
56 Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A et al. Tumour Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2018; 33: 853-861 e854.
57 Reichel MB, Ohgaki H, Petersen I, Kleihues P. p53 mutations in primary human lung tumours and their metastases. Mol Carcinog 1994; 9: 105-109.
58 Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.